Biocon Pharma Limited, a subsidiary of Biocon Limited, has received U.S. FDA approval for Dapagliflozin tablets (5 mg and 10 mg). This medication is indicated for the treatment of adults with type 2 diabetes mellitus, helping to improve glycemic control and reduce hospitalization risks for heart failure. This development enhances Biocon’s diabetes portfolio, which includes oral solid dosage forms, biosimilar insulin, and GLP-1 peptides, supporting their global commitment to diabetes care.
Expanding the Diabetes Portfolio
On April 8, 2026, Biocon announced that its subsidiary, Biocon Pharma Limited, successfully secured approval from the U.S. Food and Drug Administration (FDA) for Dapagliflozin tablets. The approval covers both 5 mg and 10 mg strengths, marking a significant milestone in the company’s efforts to diversify its therapeutic offerings.
Clinical Indication and Strategic Impact
The approved product is specifically designed for the treatment of adults diagnosed with type 2 diabetes mellitus. Used as an adjunct to diet and exercise, the medication serves a dual purpose: it helps patients achieve better glycemic control and is also indicated to reduce the risk of hospitalization for heart failure in patients with established cardiovascular disease or multiple cardiovascular risk factors.
This approval strengthens Biocon’s integrated approach to the diabetes market. By adding this product to an existing portfolio that already spans biosimilar insulin, complex GLP-1 peptides, and various oral solid dosage formulations, the company continues to bolster its capability to meet the diverse needs of patients living with diabetes globally.
Manufacturing and Quality Commitment
The production of the new Dapagliflozin tablets will take place at Biocon’s FDA-approved facilities. The company has reaffirmed its commitment to maintaining strict adherence to global quality and regulatory standards throughout the manufacturing process.
Source: BSE
